Disseminated Herpes Simplex Virus Type 2 after Treatment with Idelalisib - BJSTR Journal
Disseminated Herpes Simplex Virus Type 2 after Treatment with Idelalisib by Joseph Attallah* in Biomedical Journal of Scientific & Technical Research https://biomedres.us/fulltexts/BJSTR.MS.ID.002560.php Introduction: Case reports describing disseminated Herpes simplex virus type 2 (HSV-2) disease are limited. To our knowledge, this is the first report of disseminated HSV-2 infection in a patient who was treated by idelalisib.Case: A 62-year-old female with chronic lymphocytic leukemia (CLL) presented with a painful pruritic rash. Her skin exam showed multiple erythematous papular lesions with central necrosis. Polymerase chain reaction in the peripheral blood and skin lesions was positive for HSV-2. The diagnosis of idelalisib-associated disseminated HSV-2 was made and the patient was started on IV acyclovir. On follow-up, her skin lesions completely resolved in six weeks. Idelalisib was stopped and the patient was started on venetoclax.Discussion: Idelalisib is a highly specific phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor that was approved by the FDA for the treatment of relapsed chronic lymphocytic leukemia, in combination with rituximab, relapsed follicular B-cell nonHodgkin lymphoma, and in relapsed small lymphocytic lymphoma. This case highlights the potential cutaneous manifestation in immunocompromised individuals, which is often atypical and poses a difficulty in diagnosis. Physicians should consider HSV-2 as a rare but important cause of a disseminated rash in immunocompromised individuals. Antivirals including acyclovir and valacyclovir can successfully treat HSV-2 associated skin infection.Abbreviations: CLL: Chronic Lymphocytic Leukemia; HSV: Herpes Simplex Virus; DLBCL: Diffuse Large B-Cell Lymphoma; FCR: Fludarabine, Cyclophosphamide and RituximabIntroductionCase reports describing disseminated Herpes simplex virus type 2 (HSV-2) disease are limited. We present a case of disseminated (HSV-2) cutaneous disease in a 62-year- old female with a history of diffuse large B-cell lymphoma who began idelalisib three weeks prior to her presentation. To our knowledge, this is the first report of disseminated HSV-2 infection in a patient who was treated by idelalisib.Case ReportA 62-year-old female with a history of chronic lymphocytic leukemia (CLL) with Richter’s transformation to diffuse large B-cell lymphoma presented with a painful pruritic rash on her extremities, low-grade fever, fatigue and loss of appetite. The patient was diagnosed with stage 1 chronic lymphocytic leukemia in 2006. She had six cycles of fludarabine, cyclophosphamide, and rituximab (FCR) and achieved a complete remission. In 2012 she developed a left inguinal lymph node, and a biopsy showed progression to diffuse large B-cell lymphoma (DLBCL). The patient received six cycles of rituximab, cyclophosphamide, doxorubicin, vincristine, prednisone, and rituximab (R-CHOP) treatment. A PET scan showed a new uptake in neck, axilla and subcutaneous right lateral chest wall. Two cycles of platinum-based salvage chemotherapy with rituximab, ifosfamide, carboplatin, and etoposide (RICE) were given. Follow-up PET scan showed progression of the disease so two cycles of cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD) plus rituximab were given. For more articles on Journals on Vaccination please click here bjstr Follow on Twitter : https://twitter.com/Biomedres01 Follow on Blogger : https://biomedres01.blogspot.com/ Like Our Pins On : https://www.pinterest.com/biomedres/














